ReviewCurrent opinion in immunology2016
DNA-reactive B cells in lupus.
Review in Current opinion in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Systemic Lupus Erythematosus and DNA Degradation and Elimination Defects.Frontiers in immunology · 2019Pooled it
- Type I interferons enhance B cell activation and promote differentiation of double negative 2 cells in SLE.Lupus science & medicine · 2026Article
- Estrogen Modulation of B Cell Immunity: Implications for HIV Control and Therapeutic Strategies.Comprehensive physiology · 2025Review
- The Binding Properties of Antibodies to Z-DNA in the Sera of Normal Healthy Subjects.International journal of molecular sciences · 2024Article
- Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis.Frontiers in medicine · 2024Review
- The axis of complement C1 and nucleolus in antinuclear autoimmunity.Frontiers in immunology · 2023Review
- Measurement of circulating CD21Scientific reports · 2022Article
- The Interaction of Anti-DNA Antibodies with DNA: Evidence for Unconventional Binding Mechanisms.International journal of molecular sciences · 2022Review
- Regulation of T-independent B-cell responses by microRNA-146a.Frontiers in immunology · 2022Article
- The Binding Mechanisms of Antibodies to DNA from Healthy Subjects and Patients with Systemic Lupus Erythematosus: The Role of Monogamous Bivalency and Fc Dependence.ImmunoHorizons · 2021Article
- Meant to B: B cells as a therapeutic target in systemic lupus erythematosus.The Journal of clinical investigation · 2021Review
- B Cell Intrinsic STING Signaling Is Not Required for Autoreactive Germinal Center Participation.Frontiers in immunology · 2021Article
- Article
- Extrafollicular responses in humans and SLE.Immunological reviews · 2019Review
- Selenium supplementation suppresses immunological and serological features of lupus in B6.Sle1b mice.Autoimmunity · 2019Article
- Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects.Frontiers in immunology · 2019Review
- DNA as a self-antigen: nature and regulation.Current opinion in immunology · 2018Review
- Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Sex Hormones in Acquired Immunity and Autoimmune Disease.Frontiers in immunology · 2018Review
- Lineage-Specific Functionality of an Interferon Regulatory Factor 5 Lupus Risk Haplotype: Lack of B Cell Intrinsic Effects.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
IgG anti-DNA antibodies are both diagnostic and pathogenic for systemic lupus erythematosus (SLE). They contribute to tissue inflammation through direct tissue binding and to systemic inflammation through activation of Toll-like receptors by nucleic acid-containing immune complexes. IgG DNA-reactive antibodies originate when B cell tolerance mechanisms are impaired. The heterogeneous immune perturbations in SLE lead to the survival and activation of DNA-reactive B cells in various B cell subsets at distinct stages of B cell maturation and differentiation. We propose that the spectrum of B cell alterations and failed tolerance mechanisms for DNA-reactive B cells in lupus patients is best understood by studying genetic risk alleles. This implies that the B cells producing IgG anti-DNA antibodies and the failed tolerance mechanisms(s) will differ across patients. A better understanding of these differences should lead to better patient stratification, improved outcomes of clinical trials, and the identification of novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.